146 related articles for article (PubMed ID: 35992118)
1. What is the status of immunotherapy in thyroid neoplasms?
Garcia-Alvarez A; Hernando J; Carmona-Alonso A; Capdevila J
Front Endocrinol (Lausanne); 2022; 13():929091. PubMed ID: 35992118
[TBL] [Abstract][Full Text] [Related]
2. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
Goh D; Lim KH; Sudirman SRB; Ang MK; Chua MLK; Lim CM
Chin Clin Oncol; 2023 Oct; 12(5):57. PubMed ID: 37964542
[TBL] [Abstract][Full Text] [Related]
3. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for endocrine tumours: a clinician's perspective.
Angelousi A; Tzoulis P; Tsoli M; Chatzellis E; Koumarianou A; Kaltsas G
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38235757
[TBL] [Abstract][Full Text] [Related]
5. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y; Li P; Feng C; Cao Y
Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
[TBL] [Abstract][Full Text] [Related]
6. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.
Ferrari SM; Fallahi P; Galdiero MR; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Varricchi G; Marone G; Antonelli A
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500315
[TBL] [Abstract][Full Text] [Related]
7. New treatment modalities in advanced thyroid cancer.
Kapiteijn E; Schneider TC; Morreau H; Gelderblom H; Nortier JWR; Smit JWA
Ann Oncol; 2012 Jan; 23(1):10-18. PubMed ID: 21471561
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Immunity to Treat Advanced Thyroid Cancer.
Komatsuda H; Kono M; Wakisaka R; Sato R; Inoue T; Kumai T; Takahara M
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250858
[TBL] [Abstract][Full Text] [Related]
9. Thyroid cancer.
Chen DW; Lang BHH; McLeod DSA; Newbold K; Haymart MR
Lancet; 2023 May; 401(10387):1531-1544. PubMed ID: 37023783
[TBL] [Abstract][Full Text] [Related]
10. Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma.
Boudin L; Morvan JB; Thariat J; Métivier D; Marcy PY; Delarbre D
Curr Oncol; 2022 Oct; 29(10):7718-7731. PubMed ID: 36290887
[TBL] [Abstract][Full Text] [Related]
11. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.
Xu S; Wang C; Yang L; Wu J; Li M; Xiao P; Xu Z; Xu Y; Wang K
Front Immunol; 2023; 14():1199631. PubMed ID: 37313405
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
Gao X; Hong C; Xie Y; Zeng X
Front Oncol; 2023; 13():1103147. PubMed ID: 37007127
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
14. Research progress of immunotherapy against anaplastic thyroid cancer.
Chen J; Xiao Z; Wu H
Front Oncol; 2024; 14():1365055. PubMed ID: 38595813
[TBL] [Abstract][Full Text] [Related]
15. Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023).
Liu S; Yan X; Yang Y; Xia Y; Zhang P
Front Oncol; 2024; 14():1330030. PubMed ID: 38420016
[TBL] [Abstract][Full Text] [Related]
16. Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials.
Wang K; Zhang Y; Xing Y; Wang H; He M; Guo R
Discov Oncol; 2024 Feb; 15(1):50. PubMed ID: 38403820
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Cortas C; Charalambous H
Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38255638
[TBL] [Abstract][Full Text] [Related]
18. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC).
Huang J; Wu Q; Geller DA; Yan Y
J Transl Med; 2023 Nov; 21(1):815. PubMed ID: 37968714
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
